Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorH. Lee Moffitt Cancer Center and Research Institute
About this trial
The study aims to improve our understanding of how quality of life, fatigue, and symptoms change over 2 years when participants are treated for chronic lymphocytic leukemia or small lymphocytic lymphoma. We will compare two types of treatment to help future patients with chronic lymphocytic leukemia or small lymphocytic lymphoma know what to anticipate.
Eligibility criteria
Qualifiers
All patients with pathology-confirmed diagnoses of CLL who are within seven days of starting treatment with a BTKi +/- an anti-CD 20 monoclonal antibody or BCL2i with Obinutuzumab treatment will be included.
Subjects must be able to read and speak English or Spanish at the 8th grade level.
Disqualifiers
Patients with dementia, traumatic brain injury, or individuals with central nervous system involvement of their leukemia will be excluded from study participation.
Trial design
Treatments tested in this trial
- Bruton's tyrosine kinase inhibitor
- B-Cell Lymphoma 2 Protein Inhibitor
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
H. Lee Moffitt Cancer Center and Research Institute
Lead sponsor
National Comprehensive Cancer Network
Collaborator
AstraZeneca
Collaborator
Source ClinicalTrials.gov